4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 147 | 1 | 143 | −3 |
| Shares | 56.4M | 24.0K | 57.3M | +1.01M (+1.8%) |
| Value | $1.79B | $765.1K | $1.20B | −$589.6M (−32.9%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (29)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (32)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (1)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 24,016 | $765.1K |